Dr Suzanne Cole comments on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the POLO trial.
This was a phase III randomised trial in which olaparib was administered to patients with BRCA-related pancreatic cancer who had not progressed after initial chemotherapy and compared with placebo.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
